At what prices did the CRL stock option exercise and share sale occur?

The option exercise occurred at an exercise price of $194.12 per share, and the subsequent sale of CRL common stock was executed at $294.12 per share, each involving 2,039 shares.

What indirect CRL share holdings does Shannon M. Parisotto report after these transactions?

The Form 4 shows indirect holdings of 9,680 CRL common shares held “By Trust” and 28,510 CRL common shares held through Karpathos Investments LLC, as indicated in the indirect ownership entries.

Charles River exec sells 2,039 shares at $294.12

Q: What insider transactions did CRL executive Shannon M. Parisotto report on this Form 4?

Shannon M. Parisotto reported exercising 2,039 stock options at $194.12 per share, receiving 2,039 common shares, and then selling 2,039 common shares at $294.12 per share in CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL).

Q: Were Shannon M. Parisotto’s CRL stock transactions under a Rule 10b5-1 plan?

Yes. The filing states that the exercise and sale of 2,039 CRL common shares occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 4, 2026.

Q: What is the exercise and expiration timeline for the CRL stock options involved?

The stock options exercised for 2,039 shares of CRL common stock have an exercise (or vesting) date of May 26, 2024 and an expiration date of May 26, 2033, with an exercise price of $194.12 per share.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) executive Shannon M. Parisotto, CEVP, Discovery & Safety Assessment, reported an option exercise-and-sale transaction. Parisotto exercised 2,039 stock options at an exercise price of $194.12 per share, acquiring 2,039 common shares, and then sold 2,039 common shares at $294.12 per share. The sale was made pursuant to a Rule 10b5-1 Trading Plan initially adopted on March 4, 2026. Following these transactions, Parisotto reports indirect ownership of 9,680 common shares by a trust and 28,510 common shares through Karpathos Investments LLC, as shown in the holding entries.

Insider Trade Summary 10b5-1

Exercise and Sale: 2,039 shares ($204K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Parisotto Shannon M

Role CEVP, Disc & Safety Assessment

Sold 2,039 shs ($600K)

Approx. gross sale proceeds $600K

Approx. exercise cost $396K

Approx. pre-tax spread $204K

Type	Security	Shares	Price	Value
Exercise	Stock Options (Right to Buy)	2,039	$0.00	$0.00
Exercise	Common Stock	2,039	$194.12	$396K
Sale	Common Stock ^F1	2,039	$294.12	$600K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Options (Right to Buy) — 2,039 contracts (Direct); Common Stock — 4,807 shares (Direct); Common Stock — 9,680 shares (Indirect, By Trust); Common Stock — 28,510 shares (Indirect, by Karpathos Investments LLC)

Footnotes (1)

F1. This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 4, 2026.

Key Figures

Options exercised: 2,039 shares Exercise price: $194.12 per share Sale price: $294.12 per share +5 more

8 metrics

Options exercised 2,039 shares Stock options (right to buy) exercised into common stock

Exercise price $194.12 per share Exercise price of stock options for 2,039 shares

Sale price $294.12 per share Sale of 2,039 common shares

Shares sold 2,039 shares Common stock sold following option exercise

Indirect holdings by trust 9,680 shares Common stock held indirectly, "By Trust" after reported transactions

Indirect holdings via Karpathos Investments LLC 28,510 shares Common stock held indirectly through Karpathos Investments LLC

Option expiration date May 26, 2033 Expiration date of the stock options exercised for 2,039 shares

Net buy/sell shares -2,039 shares Net shares sold across reported buy/sell transactions

Key Terms

Rule 10b5-1 Trading Plan, Stock Options (Right to Buy), indirect ownership, exercise or conversion of derivative security

4 terms

Rule 10b5-1 Trading Plan regulatory

"This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Options (Right to Buy) financial

"security_title": "Stock Options (Right to Buy)""

indirect ownership financial

"ownership_type": "indirect", "nature_of_ownership": "By Trust""

exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did CRL executive Shannon M. Parisotto report on this Form 4?

Shannon M. Parisotto reported exercising 2,039 stock options at $194.12 per share, receiving 2,039 common shares, and then selling 2,039 common shares at $294.12 per share in CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL).

Were Shannon M. Parisotto’s CRL stock transactions under a Rule 10b5-1 plan?

Yes. The filing states that the exercise and sale of 2,039 CRL common shares occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 4, 2026.

What is the exercise and expiration timeline for the CRL stock options involved?

The stock options exercised for 2,039 shares of CRL common stock have an exercise (or vesting) date of May 26, 2024 and an expiration date of May 26, 2033, with an exercise price of $194.12 per share.

What is Shannon M. Parisotto’s role at CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)?

Shannon M. Parisotto is reported as an officer of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) with the title CEVP, Discovery & Safety Assessment on this Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/20/2026 - 04:34 PM EDT Accepted by SEC EDGAR 08/20/2026 - 04:33 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parisotto Shannon M

(Last)

(First)

(Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE STREET

(Street)

WILMINGTON

MASSACHUSETTS

01887

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEVP, Disc & Safety Assessment

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/19/2026		M		2,039	A	$194.12	6,846	D
Common Stock	08/19/2026		S		2,039⁽¹⁾	D	$294.12	4,807	D
Common Stock								9,680	I	By Trust
Common Stock								28,510	I	by Karpathos Investments LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (Right to Buy)	$194.12	08/19/2026		M			2,039	05/26/2024	05/26/2033	Common Stock	2,039	$0	2,039	D

Explanation of Responses:

1. This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 4, 2026.

	/s/ Shannon M. Parisotto	08/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR